8-K - TNON - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM 8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d)

OF

THE SECURITIES EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported):

May20, 2024

TENON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-41364	45-5574718
(State<br> or other jurisdiction	(Commission File<br> Number)	(IRS<br> Employer
of<br> incorporation)		Identification<br> No.)
104 Cooper Court
---	---
Los Gatos, CA	95032
(Address<br> of principal executive offices)	(Zip<br> Code)

(408)

649-5760

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TNON	The<br> Nasdaq Stock Market LLC
Warrants	TNONW	The<br> Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements ofCertain Officers.

(b)Resignation

On May 20, 2024, Steven Van Dick informed Tenon Medical, Inc. (the “Company”) of his decision to retire and as a result, is resigning from his positions as Executive Vice President, Finance and Administration, Chief Financial Officer and Assistant Secretary effective as of July 31, 2024. The Company is actively searching for a qualified candidate to fill the role of Chief Financial Officer. Subsequent to July 31, 2024, Mr. Van Dick will consult with the Company to continue to assist with the transition of his responsibilities and provide strategic advice as requested.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> May 22, 2024	TENON MEDICAL, INC.
	By:	/s/ Steven M. Foster
	Name:	Steven<br> M. Foster
	Title:	Chief<br> Executive Officer and President